Key result
In patients with acute STEMI, administration of RAS blockers during hospitalization was associated with a lower rate of atrial fibrillation (7.2% vs. 28.6%, P<0.001), whereas previous use was not.
Why the study?
Does the use of renin-angiotensin system blockers reduce the development of in-hospital atrial fibrillation in patients with acute STEMI?
Observational (n=1,000)
Does the use of renin-angiotensin system blockers reduce the development of in-hospital atrial fibrillation in patients with acute STEMI?
In-hospital initiation, but not prior use, of RAS blockers is associated with a significantly lower rate of new-onset atrial fibrillation in patients with acute STEMI.
Prior RAS blocker use was associated with lower post-STEMI AF incidence; leaves open whether this supports routine use or requires RCT confirmation.
BACKGROUND AND AIM: Atrial fibrillation (AF) is the most common supraventricular arrhythmia following ST-segment elevation myocardial infarction (STEMI). We evaluated the association between use of previous angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers (renin-angiotensin system [RAS] blockers) and started RAS blockers after MI and development of AF in patients presenting with acute STEMI. MATERIALS AND METHODS: This retrospective study enrolled 1000 patients with acute STEMI who were admitted to the coronary care unit. Patients were divided into groups according to the use of RAS blockers before MI and development of AF rates was compared. Predictors of AF were determined by multiple logistic regression analysis. RESULTS: Of the 1000 patients presenting with STEMI, 247 received and 753 did not receive RAS blockers. The incidence of AF was 7.9%. The incidence of AF in patients receiving RAS blockers and did not receiving RAS blockers before MI were similar (5.7% vs. 8.6% respectively, P=0.13). On the other hand, AF rate was lower in patients in whom RAS blockers were administered during MI as compared to those in whom these agents were not administered (7.2% vs. 28.6%, P<0.001). Multiple regression analysis results showed that administration of RAS blockers or statins during hospitalization and left atrial diameter were associated with development of AF in patients with acute STEMI. CONCLUSIONS: Previous therapy with RAS blockers does not reduce the incidence of AF in STEMI. Administration of RAS blockers at the hospital may decrease the AF rate in STEMI.
No takes yet. Share an insight, caveat, or question.
Arslan et al. (2016) conducted an observational in ST-segment elevation myocardial infarction (STEMI) (n=1,000). Renin-angiotensin system (RAS) blockers vs. No RAS blockers was evaluated on Development of in-hospital atrial fibrillation (p=<0.001). In patients with acute STEMI, administration of RAS blockers during hospitalization was associated with a lower rate of atrial fibrillation (7.2% vs. 28.6%, P<0.001), whereas previous use was not.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: